CN105228651A - 表征醋酸格拉替雷相关的药品 - Google Patents

表征醋酸格拉替雷相关的药品 Download PDF

Info

Publication number
CN105228651A
CN105228651A CN201480008231.5A CN201480008231A CN105228651A CN 105228651 A CN105228651 A CN 105228651A CN 201480008231 A CN201480008231 A CN 201480008231A CN 105228651 A CN105228651 A CN 105228651A
Authority
CN
China
Prior art keywords
cells
group
genes
glatiramer acetate
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480008231.5A
Other languages
English (en)
Chinese (zh)
Inventor
瑞夫卡·施瓦兹
什洛莫·巴克什
凯文·丹尼尔·富勒
法迪·乔治·托菲克
詹森·迈克尔·芬特
本杰明·詹姆斯·爱斯金德
马克西姆·阿托莫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105228651(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN105228651A publication Critical patent/CN105228651A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480008231.5A 2013-01-04 2014-01-02 表征醋酸格拉替雷相关的药品 Pending CN105228651A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361749228P 2013-01-04 2013-01-04
US61/749,228 2013-01-04
US201361819481P 2013-05-03 2013-05-03
US61/819,481 2013-05-03
PCT/US2014/010103 WO2014107533A2 (en) 2013-01-04 2014-01-02 Characterizing a glatiramer acetate related drug product

Publications (1)

Publication Number Publication Date
CN105228651A true CN105228651A (zh) 2016-01-06

Family

ID=51061235

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480008231.5A Pending CN105228651A (zh) 2013-01-04 2014-01-02 表征醋酸格拉替雷相关的药品

Country Status (17)

Country Link
US (1) US20140193827A1 (https=)
EP (1) EP2941274A4 (https=)
JP (1) JP2016504039A (https=)
KR (1) KR20150111945A (https=)
CN (1) CN105228651A (https=)
AU (1) AU2014204043A1 (https=)
BR (1) BR112015016169A2 (https=)
CA (1) CA2896957A1 (https=)
CL (1) CL2015001915A1 (https=)
EA (1) EA201591251A1 (https=)
HK (1) HK1216299A1 (https=)
IL (2) IL239692A0 (https=)
MX (1) MX2015008754A (https=)
PE (1) PE20151980A1 (https=)
SG (1) SG11201505210RA (https=)
WO (1) WO2014107533A2 (https=)
ZA (1) ZA201505367B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115044684A (zh) * 2022-06-22 2022-09-13 四川大学华西医院 lcn2基因作为生物标记物在检测Stat5基因是否缺失中的用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
CN105377308B (zh) 2013-03-14 2019-07-26 迈兰公司 醋酸格拉替雷响应生物标志物mRNA效力测定
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9995734B2 (en) 2013-10-24 2018-06-12 Mylan Inc. Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
WO2017087866A1 (en) 2015-11-20 2017-05-26 Grand Valley State University Nato3 mutant polypeptides and uses thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
JP7276664B2 (ja) * 2016-11-11 2023-05-18 ロングエバーオン インコーポレイテッド 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156826A1 (en) * 2002-09-27 2004-08-12 Fernando Dangond Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
CN1308683C (zh) * 2001-12-04 2007-04-04 特瓦制药工业有限公司 测量醋酸格拉默功效的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509142A (ja) * 2005-09-19 2009-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 調節性Ｔ細胞機能をモジュレート（ｍｏｄｕｌａｔｅ）し得るＧＰＲ８３アゴニストおよびＧＰＲ８３アンタゴニストを同定するための方法
US8753833B2 (en) * 2007-06-21 2014-06-17 Momenta Pharmaceuticals, Inc. Copolymer assay
EP2365825A1 (en) * 2008-11-18 2011-09-21 Crossbeta Biosciences B.V. Cross-beta structures as carriers in vaccines
NZ598661A (en) * 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308683C (zh) * 2001-12-04 2007-04-04 特瓦制药工业有限公司 测量醋酸格拉默功效的方法
US20040156826A1 (en) * 2002-09-27 2004-08-12 Fernando Dangond Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANAT ACHIRON ET AL.: "Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis", 《DISEASE MARKERS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115044684A (zh) * 2022-06-22 2022-09-13 四川大学华西医院 lcn2基因作为生物标记物在检测Stat5基因是否缺失中的用途

Also Published As

Publication number Publication date
CL2015001915A1 (es) 2016-11-11
BR112015016169A2 (pt) 2017-07-11
EA201591251A1 (ru) 2016-05-31
KR20150111945A (ko) 2015-10-06
IL252547A0 (en) 2017-07-31
IL239692A0 (en) 2015-08-31
SG11201505210RA (en) 2015-07-30
EP2941274A4 (en) 2016-11-16
PE20151980A1 (es) 2016-01-15
ZA201505367B (en) 2016-11-30
MX2015008754A (es) 2016-04-11
WO2014107533A2 (en) 2014-07-10
EP2941274A2 (en) 2015-11-11
US20140193827A1 (en) 2014-07-10
HK1216299A1 (zh) 2016-11-04
WO2014107533A3 (en) 2015-01-29
AU2014204043A1 (en) 2015-08-13
CA2896957A1 (en) 2014-07-10
JP2016504039A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
CN105228651A (zh) 表征醋酸格拉替雷相关的药品
US20240180976A1 (en) Microbial consortium and uses thereof
Kenna et al. Enrichment of circulating interleukin‐17–secreting interleukin‐23 receptor–positive γ/δ T cells in patients with active ankylosing spondylitis
Esposito et al. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity
Martin et al. Phenotypic and functional alterations in circulating memory CD8 T cells with time after primary infection
US20210283217A1 (en) Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseases
EP3459565A1 (en) Methods for treating hair loss disorders
EP3866835B1 (en) Method for monitoring autoimmune disease
AU2016265726A1 (en) Detection of T cell exhaustion or lack of T cell costimulation and uses thereof
Satoh et al. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients
McKay et al. The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies
Gao et al. Clonal GZMK+ CD8+ T cells are identified as a hallmark of the pathogenesis of cGVHD-induced bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation
US20170003277A1 (en) Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
Bailin et al. Changes in subcutaneous white adipose tissue cellular composition and molecular programs underlie glucose intolerance in persons with HIV
Yang et al. Lung tissue–resident memory T cells optimize protection by IL-10 regulation of innate immunity
TW201610169A (zh) 利用哺乳動物及人類細胞進行之格拉雷姆（ｇｌａｔｉｒａｍｅｒ）乙酸鹽相關藥物產品之生物特徵化
EP3247384B1 (en) In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
US11208475B1 (en) Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
CA3249433A1 (en) SYSTEMS AND METHODS FOR CLASSIFYING THE STATE OF A GRAFTING
Luo et al. Single-cell RNA analysis of chemokine expression in heterogeneous CD14+ monocytes with lipopolysaccharide-induced bone resorption
WO2018053109A1 (en) Gene expression characterization of a glatiramer acetate related drug product in mammalian and human cells
Leveque et al. T helper cell-licensed mast cells promote inflammatory Th17 cells
Mescheriakova et al. Genetics of multiple sclerosis
Tariq et al. Type-1 interferon-driven innate and GZMK+ CD8 T cell activation precedes subclinical joint inflammation when rheumatoid arthritis is imminent
Liu Transcriptional signatures of microglial innate immune memory in models of Parkinson’s and Huntington’s disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160106